Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AVP-786

- PMLiVE

Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease

The new approach would allow doctors to identify the disease at an early stage and provide treatment and support to patients sooner

- PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug

Those receiving the drug experienced a significantly slower decline than usual

- PMLiVE

EIT Health and Biogen announce winners of first ‘neurotechprize’

The winners, Five Lives and Neurocast, were among ten finalists working to create tech solutions for Alzheimer’s disease

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

There are no approved treatment options available for acute agitation related to dementia

- PMLiVE

FDA grants Prothena fast-track designation for next-generation Alzheimer’s disease therapy

Approximately 50 million people worldwide are estimated to be living with Alzheimer’s disease or other dementias

- PMLiVE

Biogen retracts EMA application for Alzheimer’s drug Aduhelm

The application was pulled after the CHMP said the data provided was not enough to support a marketing authorisation

- PMLiVE

Study provides new insights into Alzheimer’s disease

The study used the genomes of 100,000 people with Alzheimer’s and 600,000 healthy individuals

Biogen Idec building

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease

- PMLiVE

AbbVie acquires Syndesi Therapeutics in $1bn deal

The deal will allow AbbVie to access Syndesi’s research into Alzheimer's disease

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

- PMLiVE

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Phase 2 data shows lecanemab offers a consistent ‘robust’ effect against Alzheimer’s disease, while the phase 3 programme will test plasma biomarkers to identify preclinical disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links